PharmaMar and Jazz sign $1bn US deal for lung cancer drug lu...

Spain's PharmaMar and Jazz Pharmaceuticals have signed a $1 billion license agreement for the lung cancer drug lurbinectedin in the US, which is being teed up for a launch in 2020.

Novartis’ Mayzent, Roche’s Polivy head latest crop of CHMP a...

Priority review voucher prices fall again after Spark's $110...

Voucher prices have fallen since their 2015 peak

EUSA Pharma looks to further in-licensing to build growth

Specialist company EUSA Pharma is looking for new medicines to develop after getting two cancer drugs recommended by European regulators this year.